Addressing disparities in prostate cancer requires the ability to recognize that care inequities exist and the commitment to provide equitable care to all patients. This is not an easy undertaking—but an essential one for any healthcare team.

The Association of Community Cancer Centers (ACCC) identified four cancer programs that have developed—or are developing—strategies to overcome disparities in prostate cancer care. Their efforts demonstrate a broad range of approaches to creating change and improving prostate cancer detection and treatment.

This webinar highlights four effective community outreach strategies to overcome disparities in prostate cancer care.
View On-Demand

This webinar is open to the public. You do not need to be an ACCC member to view this webinar, but you will need to create an account in order to register. Please click the "Registration Instructions" tab for more details.

Focus Area: Connecting with Faith Communities
Sutricia Johnson, BSN, eMBA
Director of Case Management
Chelsea Kroll, LMSW, OSW-C
Certified Oncology Social Worker
Spencer Cancer Center

Focus Area: Outreach Strategies to Increase Early Detection through Community Health Outreach and Education Program
Nora C. Katurakes, MSN, RN, OCN
Manager, Community Health Outreach and Education
ChristianaCare’s Helen F. Graham Cancer Center & Research Institute

Focus Area: Facilitated Peer Support Group
Nynikka R. A. Palmer, DrPH, MPH
Assistant Professor of Medicine, Urology, and Radiation Oncology
UCSF Helen Diller Family Comprehensive Cancer Center

Focus Area: Community Outreach Aspects of Three-Year Institutional Grant Offering Multidisciplinary Prostate Cancer Care to High-Risk and Socioeconomically Disadvantaged Men Throughout Central Ohio
Shawn Dason, MD
Urologic Oncologist, Assistant Professor of Urology
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University

This webinar is part of the Overcoming Prostate Cancer Disparities in Care education project. Supported by an educational grant from AstraZeneca and Merck.